The sustained release excipients market has seen considerable growth due to a variety of factors.
•In recent times, the market size for sustained release excipients has experienced considerable growth. The market is expected to rise from a value of $1.4 billion in 2024 to reach $1.53 billion in 2025, indicating a compound annual growth rate (CAGR) of 9.1%.
This growth during the historic period can be traced back to factors such as an escalating demand for controlled drug release, the pervasiveness of chronic diseases, improving patient compliance and convenience. Additionally, innovations in the pharmaceutical industry and regulatory support in favor of extended-release formulations have also contributed to the growth.
The sustained release excipients market is expected to maintain its strong growth trajectory in upcoming years.
• Over the coming years, the sustained release excipients market is projected to experience robust growth, reaching a market size of "$2.13 billion by 2029 with a compound annual growth rate (CAGR) of 8.8%.
This anticipated growth within the forecast window can be attributed to factors such as a growing elderly population, an emphasis on personalized healthcare, difficulties with patient compliance, an increase in complex pharmaceutical formulations, progress in disease management, and the global expansion of healthcare. Trends that are expected to shape the market during the forecast period are the adoption of patient-centered drug delivery, strategic partnerships for formulation development, adherence to regulatory and safety standards, the global advancement of drug formulation technologies, and the impactful role of biopharmaceuticals.
The rise in chronic and acute diseases is anticipated to spur the sustained-release excipients market's expansion. Distinctly categorized, chronic diseases refer to medical conditions lasting for a lengthy period, usually three months or above, while acute diseases present sudden, severe symptoms that last for a short time, from hours to days or weeks. Sustained-release excipients, which are extensively utilized in the creation of pharmaceutical products for both types of diseases, enhance patient compliance, maintain steady drug levels, minimize side-effects, and enhance disease management. These benefits contribute to the increased sales of these excipients. For example, the World Health Organization (WHO) reported in September 2022 that heart diseases were responsible for the highest number of NCD deaths, claiming 17.9 million lives every year. This was followed by chronic respiratory diseases (4.1 million), diabetes (2.0 million, including deaths from kidney disease exacerbated by diabetes), and cancer (9.3 million). Similarly, a report published by the American College of Cardiology in August 2022 projected that all four main cardiovascular risk factors would rise from 2025 to 2060 in the USA. Diabetes is predicted to see the biggest percentage surge, at 39.3% increase to 55 million individuals, followed by dyslipidemia (27.6% to 126 million), hypertension (25.1% to 162 million), and obesity (18.3% to 126 million). There are also predictions for critical increases in rates of stroke (33.8% to 15 million) and heart failure (33.4% to 13 million), accompanied by ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million). Thus, the growing prevalence of chronic and acute diseases fuels the rise of the sustained-release excipients market.
The sustained release excipients market covered in this report is segmented –
1) By Product: Gelatin, Polymers, Minerals, Sugars, Alcohol, Chitosan
2) By Route of Administration: Oral, Intramuscular, Subcutaneous, Transdermal, Vaginal, Ophthalmic, Intravenous, Other Routes of Administration
3) By Technology: Targeted Delivery, Micro Encapsulation, Wurster Technique, Transdermal, Implants, Coacervation
Subsegments:
1) By Gelatin: Type A Gelatin, Type B Gelatin
2) By Polymers: Natural Polymers, Synthetic Polymers
3) By Minerals: Calcium Compounds, Magnesium Compounds, Other Mineral Excipients
4) By Sugars: Sucrose, Lactose, Glucose, Other Sugars
5) By Alcohol: Ethanol, Isopropyl Alcohol, Other Alcohols
6) By Chitosan: Low Molecular Weight Chitosan, High Molecular Weight Chitosan
The trend of product innovation is increasingly prominent in the sustained release excipients market. Big players in the market are launching unique products to consolidate their market positions. For example, Nutriventia Limited, a pharmaceutical company based in India, introduced Prolanza to the market in September 2022. This is a sustained-release ingredient derived from the ashwagandha plant (Withania somnifera). Prolanza is a sophisticated extract derived solely from Ashwagandha root that provides enduring relief from stress. The special release method of Prolanza allows it to show its healing effects over a prolonged period with just a single daily dosage. Compared to its control component, Prolanza ashwagandha showed enhanced relative absorption, increased bioavailability, and extended elimination half-life, indicating a sustainable release profile. As ashwagandha is known for its adaptability and its role in reducing stress responses, the long-lasting therapeutic effects of Prolanza can significantly contribute to overall health. Produced from natural herbs, its profitability has been clinically validated.
Major companies operating in the sustained release excipients market include:
• BASF SE
• Ashland Global Holdings Inc.
• Colorcon Inc.
• Croda International Plc
• Dow Chemical Company
• DuPont de Nemours Inc.
• Roquette Frères
• Evonik Industries AG
• Lubrizol Corporation
• Merck KGaA
• JRS Pharma GmbH & Co. KG
• Shin-Etsu Chemical Co.Ltd.
• Gattefossé SAS
• Eastman Chemical Company
• Cellulose Solutions Private Limited
• Avantor Inc.
• SPI Pharma Inc.
• Asahi Kasei Corporation
• Chemische Fabrik Budenheim KG
• Associated British Foods plc
• Ransom Naturals Ltd
• Balchem Corporation
• IMCD Group
• Lonza Group AG
North America was the largest region in the global sustained release excipients market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sustained release excipients market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa